Inncanex’s anti-inflammatory and COVID-19 drug candidate showing promise in pre-clinical studies

Special Report: Incannex Healthcare (ASX:IHL) says its hydroxychloroquine/cannabidiol combination drug IHL-675A is vastly outperforming CBD alone in fighting inflammation in … Read More

The post Inncanex’s anti-inflammatory and COVID-19 drug candidate showing promise in pre-clinical studies appeared first on Stockhead.

You May Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *